These independent studies provide further evidence that glucagon, at plasma concentrations that prevail most of the time in vivo, even in type 2 diabetes, produces robust intracellular effects leading to enhanced glucose output by activating the PLC/IP3 pathway without activating the AC/cAMP pathway. This evidence concerns the gene HSPG2 and type 2 diabetes mellitus.